Amarantus to Present at Sachs Associates 14th Annual Biotech in Europe Forum for Global Partnering and Investment


SAN FRANCISCO and GENEVA, Sept. 4, 2014 (GLOBE NEWSWIRE) -- Amarantus Bioscience Holdings, Inc. (OTCQB:AMBS), a biotechnology company focused on the development of diagnostic and therapeutic interventions for Alzheimer's disease, Parkinson's disease and orphan ophthalmological disorders, announced that Gerald E. Commissiong, President and CEO, is scheduled to present at the 14th Annual Biotech in Europe Forum at the Congress Center in Basel, Switzerland. The presentation is scheduled for Wednesday, October 1st at 11:45 AM in the Darwin Room. Mr. Commissiong's presentation will be web cast live and available on the company's web site at www.amarantus.com.

Additional information about the conference may be found at www.sachsforum.com. Attendees who wish to meet with management one on one may contact our Investor Relations department at ir@amarantus.com

About Amarantus BioScience Holdings, Inc.

Amarantus BioScience Holdings (AMBS) is a biotechnology company developing treatments and diagnostics for diseases associated with neurodegeneration and protein misfolding-related apoptosis. AMBS has licensed Eltoprazine ("Eltoprazine"), a phase 2b ready small molecule indicated for Parkinson's Levodopa induced dyskinesia and Adult ADHD. AMBS has an exclusive worldwide license to the Lymphocyte Proliferation test ("LymPro Test(R)") for Alzheimer's disease and owns the intellectual property rights to a therapeutic protein known as Mesencephalic-Astrocyte-derived Neurotrophic Factor ("MANF") and is developing MANF-based products as treatments for brain disorders. AMBS also owns intellectual property for the diagnosis of Parkinson's disease ("NuroPro") and the discovery of neurotrophic factors ("PhenoGuard"). Amarantus operations are located at Janssen Labs @QB3 in San Francisco, CA. For further information please visit www.Amarantus.com, or connect with the company on Facebook, LinkedIn, Twitter and Google+.



            

Contact Data